Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
On the heels of his study, Dr. James Berenson an oncologist specializing in multiple myeloma —announced his latest...